Company Directory > Pharma > Keenova Therapeutics (formerly Endo Pharmaceuticals/Mallinckrodt Specialty Brands)
Keenova Therapeutics is a specialty pharmaceutical company created following the August 2025 merger of Mallinckrodt and Endo Pharmaceuticals and subsequent November 2025 spin-off of Par Health. The company develops, manufactures, and commercializes branded therapeutics focused on patients with rare or unaddressed conditions across diverse therapeutic areas including immunology, urology, hepatology, ophthalmology, orthopedics, and critical care. With 2024 pro-forma revenue of $1.7 billion and over 1,600 employees, Keenova operates a portfolio of established brands including XIAFLEX (collagenase for Dupuytren's contracture and Peyronie's disease) and Acthar Gel (corticotropin for inflammatory and autoimmune conditions), serving patients globally with a focus on high-value specialty medicines.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals|Biotechnology
Sub-Industry:Specialty Pharmaceuticals|Rare Diseases|Branded Therapeutics
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$1.7B
Founded:1990
Ownership:private
Status:operating
FUNDING
Stage:Pre-IPO
STOCK
Exchange:NYSE (planned)
Ticker:MNK (as Mallinckrodt prior to rebranding; planning 2026 NYSE listing)
Market Cap:$1.7B pro-forma
PIPELINE
Stage:Commercial|Phase 1-3
Lead Drug Stage:Commercial
Modalities:Small molecule, Biologics, Injectable
Trial Phases:-
FDA Approvals:28
CORPORATE STRUCTURE
Parent Company:Mallinckrodt PLC (as of August 2025 merger, planning IPO)
Subsidiaries:Par Health (spun off November 2025 - generics and sterile injectables)
Key Partnerships:Former partnership structure within Mallinckrodt-Endo combined entity
COMPETITION
Position:Leader
Competitors:Pfizer (Peyronie's disease), Viagra/Cialis (men's health), Various orthopedic and rare disease pharma companies
LEADERSHIP
Key Executives:
Siggi Olafsson - President and Chief Executive Officer
Rajiv Silva - CEO (Endo pre-merger)
Susan Williamson - Executive Vice President and Chief Compliance Officer
Matthew Maletta - Executive Vice President, Chief Legal Officer
Patrick Barry - EVP & Chief Commercial Officer US Branded Pharmaceuticals
Joseph Barbarite - Executive Vice President, Global Quality and Compliance
Brandon Rockwell - Senior Vice President, Business Development & Strategy
Matthew Davis - Senior Vice President - Branded Research & Development
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Keenova Therapeutics (formerly Endo Pharmaceuticals/Mallinckrodt Specialty Brands). The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.